Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Marker Therapeutics to establish cGMP manufacturing facility in Houston, TX » 07:06
06/30/20
06/30
07:06
06/30/20
07:06
MRKR

Marker Therapeutics

$2.02 /

+0.08 (+4.12%)

Marker Therapeutics…

Marker Therapeutics announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. FDA guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021. The facility has approximately 48,500 feet and will provide space for clinical manufacturing and quality functions upon completion. Marker will continue to manufacture its MultiTAA-specific T cell therapy at the Baylor College of Medicine to support the company-sponsored AML trial until the in-house cGMP manufacturing facility is operational.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.02 /

+0.08 (+4.12%)

MRKR Marker Therapeutics
$2.02 /

+0.08 (+4.12%)

05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
MRKR Marker Therapeutics
$2.02 /

+0.08 (+4.12%)

MRKR Marker Therapeutics
$2.02 /

+0.08 (+4.12%)

Hot Stocks
Marker Therapeutics announces USAN approves zelenoleucel as generic name » 07:02
06/23/20
06/23
07:02
06/23/20
07:02
MRKR

Marker Therapeutics

$2.05 /

-0.045 (-2.15%)

Marker Therapeutics…

Marker Therapeutics announced that the U.S. Adopted Names, or USAN, Council has approved "zelenoleucel" as the nonproprietary name or generic for MT-401, a multi-tumor-associated antigen, or MultiTAA,-specific T cell product candidate for the treatment of patients with acute myeloid leukemia following allogeneic stem cell transplant in both adjuvant and active disease settings. "The USAN approval of zelenoleucel as the generic name for MT-401 is another step forward for continued advancement of our therapy," said Peter L. Hoang, President & CEO of Marker Therapeutics. "MT-401, which received Orphan Drug designation from the U.S. FDA in April, has shown clinical benefit in patients with acute myeloid leukemia post stem cell transplant in an investigator-sponsored trial. We are excited about the continued clinical development of zelenoleucel and look forward to initiating our Company-sponsored Phase 2 study in patients with AML following transplant."

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.05 /

-0.045 (-2.15%)

MRKR Marker Therapeutics
$2.05 /

-0.045 (-2.15%)

05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
MRKR Marker Therapeutics
$2.05 /

-0.045 (-2.15%)

MRKR Marker Therapeutics
$2.05 /

-0.045 (-2.15%)

Hot Stocks
Marker Therapeutics reports results from MultiTAA-specific T cell therapy » 08:16
05/29/20
05/29
08:16
05/29/20
08:16
MRKR

Marker Therapeutics

$2.48 /

-0.03 (-1.20%)

Marker Therapeutics…

Marker Therapeutics announced updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the company's MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma. Between June 2018 and December 2019, 13 patients have been treated, each of whom received up to 6 monthly infusions of 1x107 MultiTAA-specific T cells/m2 in conjunction with ongoing first-line chemotherapy and without prior protocol-associated lymphodepletion. For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient. Out of the 13 evaluable patients: 4 patients experienced objective responses after administration of MultiTAA cells; 1 patient experienced a radiographic complete response occurring at month 9 after starting chemotherapy; 3 patients experienced partial responses per RECIST occurring at 6-9 months after starting chemotherapy;6 patients experienced stable disease; 1 patient experienced a mixed response (some lesions increased in size and others decreased for a net zero change in size of tumor lesions); 2 patients experienced disease progression; For 9 of the 13 patients, the cancer was controlled for a period longer than historical controls relative to the type of chemotherapy used; 5 patients enrolled in the study were not administered MultiTAA-specific T cells, either because of disease progression (4 patients) which made them ineligible for treatment, or because insufficient starting material from the patient was available for manufacturing (1 patient); Evidence of epitope-spreading was observed in all responders, suggesting that the MultiTAA T cell therapy triggered the recruitment of a broader endogenous immune system response for improved anti-tumor activity; No infusion-related reactions, cytokine release syndrome or neurotoxicity was observed.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.48 /

-0.03 (-1.20%)

MRKR Marker Therapeutics
$2.48 /

-0.03 (-1.20%)

05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
MRKR Marker Therapeutics
$2.48 /

-0.03 (-1.20%)

MRKR Marker Therapeutics
$2.48 /

-0.03 (-1.20%)

Downgrade
Fly Intel: Top five analyst downgrades » 10:13
05/12/20
05/12
10:13
05/12/20
10:13
CNP

CenterPoint Energy

$18.05 /

-0.135 (-0.74%)

, ON

ON Semiconductor

$15.49 /

-0.15 (-0.96%)

, MRKR

Marker Therapeutics

$2.31 /

-0.19 (-7.60%)

, QDEL

Quidel

$201.73 /

-7.41 (-3.54%)

, ALB

Albemarle

$62.90 /

-1.59 (-2.47%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CenterPoint Energy (CNP) downgraded to Neutral from Buy at Goldman Sachs with analyst Insoo Kim saying the company's $1.4B private placement announced last week quelled its equity needs, but he is concerned that the upfront share dilution and the demand impact related to COVID-19 will see the utility's annualized earnings growth rate through 2022 below its 5%-7% target range. 2. ON Semiconductor (ON) downgraded to Outperform from Strong Buy at Raymond James with analyst Chris Caso citing March quarter results. 3. Marker Therapeutics (MRKR) downgraded to Neutral from Overweight at Piper Sandler with analyst Edward Tenthoff saying Marker has delayed the initiation of the safety lead-in of the Phase II acute myeloid leukemia study of MultiTAA with the legacy reagent in three patients. 4. Quidel (QDEL) downgraded to Underweight from Neutral at JPMorgan with analyst Tycho Peterson saying ith the shares trading at a 34.6 times 2021 price-to-earnings ratio, Quidel's valuation more than factors in a best case scenario. 5. Albemarle (ALB) downgraded to Neutral from Buy at Goldman Sachs with analyst Robert Koort saying with the growing ramifications of the COVID-19 pandemic, the anticipated ascension of the lithium cycle will be further delayed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
QDEL Quidel
$201.73 /

-7.41 (-3.54%)

ON ON Semiconductor
$15.49 /

-0.15 (-0.96%)

MRKR Marker Therapeutics
$2.31 /

-0.19 (-7.60%)

CNP CenterPoint Energy
$18.05 /

-0.135 (-0.74%)

ALB Albemarle
$62.90 /

-1.59 (-2.47%)

CNP CenterPoint Energy
$18.05 /

-0.135 (-0.74%)

05/11/20 Goldman Sachs
CenterPoint Energy downgraded to Neutral from Buy at Goldman Sachs
05/08/20 BofA
CenterPoint Energy downgraded to Underperform after rally at BofA
05/08/20 BofA
CenterPoint Energy downgraded to Underperform from Neutral at BofA
04/03/20 Wolfe Research
CenterPoint Energy upgraded to Outperform from Peer Perform at Wolfe Research
ON ON Semiconductor
$15.49 /

-0.15 (-0.96%)

05/12/20 Loop Capital
ON Semiconductor price target lowered to $17 from $18 at Loop Capital
05/12/20 Raymond James
ON Semiconductor downgraded to Outperform at Raymond James on valuation
05/12/20 Mizuho
ON Semiconductor price target lowered to $21 from $24 at Mizuho
05/12/20 Raymond James
ON Semiconductor downgraded to Outperform from Strong Buy at Raymond James
MRKR Marker Therapeutics
$2.31 /

-0.19 (-7.60%)

05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
QDEL Quidel
$201.73 /

-7.41 (-3.54%)

05/12/20 JPMorgan
JPMorgan downgrades Quidel to Underweight on COVID opportunity skepticism
05/12/20 JPMorgan
Quidel downgraded to Underweight from Neutral at JPMorgan
05/07/20 Craig-Hallum
Quidel price target raised to $170 from $125 at Craig-Hallum
03/26/20 Barclays
Quidel downgraded to Equal Weight from Overweight at Barclays
ALB Albemarle
$62.90 /

-1.59 (-2.47%)

05/12/20 Citi
Albemarle price target raised to $59 from $49 at Citi
05/12/20 Goldman Sachs
Albemarle downgraded to Neutral from Buy at Goldman Sachs
05/11/20 Truist
Albemarle price target lowered to $65 from $90 at SunTrust
04/29/20 Loop Capital
Albemarle double-downgraded at Loop Capital to Sell from Buy
QDEL Quidel
$201.73 /

-7.41 (-3.54%)

ON ON Semiconductor
$15.49 /

-0.15 (-0.96%)

MRKR Marker Therapeutics
$2.31 /

-0.19 (-7.60%)

CNP CenterPoint Energy
$18.05 /

-0.135 (-0.74%)

ALB Albemarle
$62.90 /

-1.59 (-2.47%)

CNP CenterPoint Energy
$18.05 /

-0.135 (-0.74%)

ALB Albemarle
$62.90 /

-1.59 (-2.47%)

QDEL Quidel
$201.73 /

-7.41 (-3.54%)

ON ON Semiconductor
$15.49 /

-0.15 (-0.96%)

MRKR Marker Therapeutics
$2.31 /

-0.19 (-7.60%)

ALB Albemarle
$62.90 /

-1.59 (-2.47%)

ON ON Semiconductor
$15.49 /

-0.15 (-0.96%)

CNP CenterPoint Energy
$18.05 /

-0.135 (-0.74%)

ALB Albemarle
$62.90 /

-1.59 (-2.47%)

Downgrade
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler » 04:54
05/12/20
05/12
04:54
05/12/20
04:54
MRKR

Marker Therapeutics

$2.50 /

+0.1 (+4.17%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff downgraded Marker Therapeutics to Neutral from Overweight with a price target of $2.50, down from $5. Marker has delayed the initiation of the safety lead-in of the Phase II acute myeloid leukemia study of MultiTAA with the legacy reagent in three patients, Tenthoff tells investors in a research note. The analyst cites further study delays for the downgrade.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.50 /

+0.1 (+4.17%)

MRKR Marker Therapeutics
$2.50 /

+0.1 (+4.17%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
MRKR Marker Therapeutics
$2.50 /

+0.1 (+4.17%)

MRKR Marker Therapeutics
$2.50 /

+0.1 (+4.17%)

Earnings
Marker Therapeutics reports Q1 EPS (14c), consensus (11c) » 16:21
05/11/20
05/11
16:21
05/11/20
16:21
MRKR

Marker Therapeutics

$2.50 /

+0.1 (+4.17%)

At March 31, Marker had…

At March 31, Marker had cash and cash equivalents of $40.3M. The company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into Q2 of 2021.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.50 /

+0.1 (+4.17%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
Over a quarter ago
Hot Stocks
Marker Therapeutics' Acute Myeloid Leukemia candidate designated Orphan Drug » 16:23
04/29/20
04/29
16:23
04/29/20
16:23
MRKR

Marker Therapeutics

$2.27 /

+0.3 (+15.23%)

Marker Therapeutics'…

Marker Therapeutics' MT-401, a multi-tumor-associated antigen-specific T cell product for the treatment of patients with acute myeloid leukemia has been granted Orphan Drug designation by the FDA's Office of Orphan Products Development.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.27 /

+0.3 (+15.23%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
On The Fly
Fly Intel: Pre-market Movers » 09:04
04/13/20
04/13
09:04
04/13/20
09:04
ATHX

Athersys

$2.88 /

-0.065 (-2.21%)

, MRKR

Marker Therapeutics

$1.75 /

+0.045 (+2.65%)

, MUR

Murphy Oil

$7.94 /

+0.61 (+8.32%)

, BCRX

BioCryst

$2.05 /

+0.065 (+3.27%)

, BA

Boeing

$151.93 /

+5.14 (+3.50%)

, TXN

Texas Instruments

$107.75 /

-2.37 (-2.15%)

, ACB

Aurora Cannabis

$0.88 /

+0.0253 (+2.97%)

, NXPI

NXP Semiconductors

$90.13 /

-1.36 (-1.49%)

, CAT

Caterpillar

$124.98 /

-2.53 (-1.98%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ATHX Athersys
$2.88 /

-0.065 (-2.21%)

08/26/19 Dawson James
Athersys initiated with a Buy at Dawson James
MRKR Marker Therapeutics
$1.75 /

+0.045 (+2.65%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
MUR Murphy Oil
$7.94 /

+0.61 (+8.32%)

04/03/20 Mizuho
Murphy Oil downgraded to Underperform from Neutral at Mizuho
03/25/20 Piper Sandler
Murphy Oil price target lowered to $3 from $34 at Piper Sandler
03/20/20 Wells Fargo
Murphy Oil can navigate turbulent environment, says Wells Fargo
03/20/20 Wells Fargo
Correction: Murphy Oil upgraded to Overweight at Wells Fargo
BCRX BioCryst
$2.05 /

+0.065 (+3.27%)

03/05/20 Piper Sandler
BioCryst's berotralstat should still be approved this year, says Piper Sandler
02/18/20 JMP Securities
JMP says BioCryst should react favorably to NDA acceptance, lack of AdComm
11/15/19
Fly Intel: Top five analyst upgrades
11/15/19 BofA
BioCryst upgraded to Buy from Neutral at BofA/Merrill
BA Boeing
$151.93 /

+5.14 (+3.50%)

04/13/20 BofA
BofA downgrades Spirit AeroSystems to Underperform, slashes price target to $25
04/09/20 Goldman Sachs
Embraer upgraded to Neutral from Sell at Goldman Sachs
04/07/20 Wells Fargo
Hexcel price target lowered to $38 from $85 at Wells Fargo
04/07/20 Berenberg
Boeing price target lowered to $150 from $350 at Berenberg
TXN Texas Instruments
$107.75 /

-2.37 (-2.15%)

04/13/20 Morgan Stanley
Morgan Stanley downgrades Texas Instruments to Underweight on gross margins risk
04/13/20 Morgan Stanley
Texas Instruments downgraded to Underweight from Equal Weight at Morgan Stanley
03/30/20 Citi
Texas Instruments price target lowered to $138 from $150 at Citi
03/27/20 UBS
UBS upgrades Semiconductor Equipment names, sees supply/demand shock priced in
ACB Aurora Cannabis
$0.88 /

+0.0253 (+2.97%)

04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
02/24/20 Cowen
Cowen cautious on Canada cannabis, downgrades Aurora, Sundial, Tilray
NXPI NXP Semiconductors
$90.13 /

-1.36 (-1.49%)

04/13/20 Evercore ISI
NXP Semiconductors downgraded to In Line from Outperform at Evercore ISI
04/08/20 Stifel
NXP Semiconductors price target lowered to $90 from $109 at Stifel
04/08/20 Mizuho
NXP Semiconductors price target lowered to $126 from $140 at Mizuho
CAT Caterpillar
$124.98 /

-2.53 (-1.98%)

04/13/20 BofA
Caterpillar downgraded to Underperform from Neutral at BofA
04/13/20 BofA
Caterpillar downgraded to Underperform from Neutral at BofA
04/09/20 Credit Suisse
Caterpillar price target lowered to $148 from $162 at Credit Suisse
04/02/20 OTR Global
Caterpillar upgraded to Mixed from Negative at OTR Global
Hot Stocks
Marker Therapeutics receives EUA from FDA for D2000 Adsorption Cartridge » 08:30
04/13/20
04/13
08:30
04/13/20
08:30
MRKR

Marker Therapeutics

$1.75 /

+0.045 (+2.65%)

Terumo BCT and Marker…

Terumo BCT and Marker Therapeutics announced that the FDA has issued Emergency Use Authorization, or EUA, for the use of Terumo BCT's Spectra Optia Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed coronavirus admitted to the intensive care unit, or ICU, with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels. The devices work together by reducing the number of cytokines and other inflammatory mediators, i.e., small active proteins in the bloodstream that control a cell's immune response by filtering the blood and returning the filtered blood to the patient. The proteins that are removed are typically elevated during infections and can be associated with a "cytokine storm" that occurs in some COVID-19 patients, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.75 /

+0.045 (+2.65%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
Hot Stocks
Marker Therapeutics sees cash runway extending beyond 2Q21  16:09
03/12/20
03/12
16:09
03/12/20
16:09
MRKR

Marker Therapeutics

$1.60 /

-0.37 (-18.78%)

 
ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.60 /

-0.37 (-18.78%)

02/11/20 Roth Capital
Roth Capital maintains Buy on Marker Therapeutics after trial hold is lifted
02/11/20 Piper Sandler
Marker Therapeutics price target trimmed to $5 at Piper Sandler on study delay
11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.